Physician profile
Devangi D Desai
NPI 1710155163
$4,220.00
in general payments reported to CMS, 2019-2025
23 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $2,262 · 2021: $562 · 2022: $158 · 2023: $241 · 2024: $402 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,212.58 | 2019-2021 | |
| Abbott Laboratories | $664.50 | 2020-2025 | Cardiomems, Mitraclip, Amplatzer Talisman |
| Edwards Lifesciences Corporation | $377.13 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal, Sapien 3 Ultra Resilia |
| Abbvie INC. | $201.57 | 2019-2023 | Vraylar |
| Glaxosmithkline, LLC. | $135.37 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.57 | 2021-2022 | |
| Boston Scientific Corporation | $94.05 | 2024-2025 | Watchman Access System, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $61.71 | 2021-2022 | |
| Pfizer INC. | $52.62 | 2019-2021 | |
| Medtronic Vascular, INC. | $50.24 | 2019 | |
| Novo Nordisk INC | $35.56 | 2021 | |
| Amarin Pharma, INC. | $32.97 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $25.74 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $23.96 | 2019 | |
| United Therapeutics Corporation | $23.19 | 2025 | Orenitram |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $20.27 | 2023 | Inpefa |
| Lilly USA, LLC | $20.10 | 2022 | |
| Akcea Therapeutics, INC. | $17.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.02 | 2021 | |
| Merck Sharp & Dohme LLC | $15.51 | 2019 | |
| Acerus Pharmaceuticals Corporation | $13.40 | 2021 | |
| Advanced Respiratory, INC | $12.87 | 2019 | |
| Cardiovascular Systems INC. | $12.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devangi Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.